Repurchase amount does not meet the standard, jilin yatai group is ordered to make corrections | Speed reading announcement

①Upon the expiration of the repurchase period, jilin yatai repurchased amount is below the lower limit of the total repurchase amount, jilin Securities Regulatory Bureau requested correction. ②Jilin Securities Regulatory Bureau decided to take regulatory measures to order the company to make corrections, and record it in the integrity files of the securities and futures market.

cls.cnNov 8 10:46 ET

Companies with long-term net asset value per share below book value must disclose plans for valuation improvement. State-owned enterprises with net asset value per share below book value are expected to attract incremental funds.

On September 24, the China Securities Regulatory Commission publicly solicited opinions on the 'Guidelines for the Supervision of Listed Companies No. 10 - Market Cap Management (Consultation Draft)'. The guidelines require long-term companies trading below net asset value to disclose their valuation enhancement plans, including targets, deadlines, specific measures, and provide special explanations on the execution of the valuation enhancement plan during the annual performance briefing.

cls.cnSep 24 19:59 ET

The State Council meeting promotes a virtuous cycle in the venture capital industry, and the sector is expected to seize the opportunity.

On September 18th, the executive meeting of the State Council pointed out that venture capital is related to technological innovation, industrial upgrading, and high-quality development. It is necessary to quickly resolve the bottlenecks and difficulties in the various stages of fundraising, investment management, and withdrawal, support eligible technology-based enterprises to list both domestically and internationally, vigorously develop the equity transfer and mergers and acquisitions market, and promote a healthy cycle in the venture capital industry.

cls.cnSep 18 19:41 ET

On September 10, 11 companies, including Tiantan Biology and China Satcom, announced positive results.

1. Tiantan Biology: Chengdu Rongsheng related production site has passed the drug GMP compliance test Tiantan Biological announcement, Chengdu Rongsheng developed "Human Coagulation Factor Ⅷ" meets the relevant requirements of drug registration. At the same time, Chengdu Rongsheng related production sites have passed the drug GMP compliance inspection, and obtained the "Drug GMP on-the-spot Inspection result notice" issued by the Sichuan Provincial Drug Administration. two。 China Satcom: China Star 9B satellite will be delivered to the company after passing the in-orbit test. China Satcom announced that the China Star 9B satellite launched on September 9 will be delivered to the company's operation management after passing the in-orbit test.

證券之星Sep 10, 2021 05:58 ET

East Sunshine strongly pulls up the daily limit, and northward funds enter the market to buy 109 million yuan.

Securities Star data Center News, according to the trading public information released by the Shanghai and Shenzhen Stock Exchange on September 3, 2021, Dongguang (600673) was on the Dragon and Tiger list because of securities with a deviation of 7%. This is the second time in the last five trading days that it has been on the list. By the end of the day, East Sunshine closed at 9.64 yuan, an increase of 10.05%, with a turnover of 1.5849 million lots. Judging from the day-to-day trading data announced by the Dragon and Tiger list, the institutions totaled a net sale of-30.1609 million yuan. Shanghai Stock Exchange bought 109.6256 million yuan, sold 48.6252 million yuan, and bought a net 6100.04 yuan.

證券之星Sep 3, 2021 05:13 ET

Analysis of the limit of East Sunshine on September 3: innovative drugs, Medicine, Avian Influenza concept Hot stocks

Securities Star data Center News, East Sunshine rose the limit to close, closing price 9.64 yuan. The stock rose by the limit at 09:45, opened the limit five times, and closed its closing order with a capital of 104 million yuan, accounting for 0.36% of its current market value. In terms of capital flow data, the net inflow of main funds on the same day was 200 million yuan, the net inflow of hot capital was 259 million yuan, and the net outflow of retail funds was 65.9267 million yuan. The capital flow in the past five days is shown in the following table: the stock is a hot stock of innovative drugs, pharmaceuticals and bird flu concepts. On the same day, innovative drug concepts rose 1.49%, medicine concepts rose 1.38%, and bird flu concepts rose 1.11%.

證券之星Sep 3, 2021 03:10 ET